Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on July 9, 2019, covering the event date of July 8, 2019. The Company is an emerging growth company incorporated in Nevada with its common stock trading on NASDAQ under the symbol INMB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a corporate administrative update and does not contain financial statements or performance data.
Material Changes
Under Item 8.01 (Other Events), the Company reported a change to its principal executive office address. The new location is 1200 Prospect Street, Suite 525, La Jolla, California, 92037.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Confirm the new principal executive office address at 1200 Prospect Street, Suite 525, La Jolla, CA 92037.
- Verify the Company's status as an emerging growth company.
- Note that this filing contains no financial performance data or strategic updates.